In June 2020, Adgero Biopharmaceuticals Holdings, Inc. was acquired by Delmar that - soon after - changed it name to Kintara Therapeutics trading on NASDAQ with new sysmbol "KTRA". A biopharmaceutical company, Adgera had been building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform holding promise as a localized cutaneous or visceral tumor treatment. Additionally, PDT has immune activating properties and has potential therapeutic utility in oncology as a combination therapy in conjunction with immunotherapies. It is also being investigated in the cardiovascular setting as treatment for hemodialysis access failure. Adgero's lead product candidate, REM-001 therapy, has been previously studied in four Phase 2/3 clinical trials in patients with cutaneous metastatic breast cancer (CMBC), who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and with an existing robust safety database of approximately 1,100 patients across multiple indications, Adgero is currently focused on advancing the REM-001 program to late stage pivotal testing.
